ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > total liabilities dropped by $8M in H1

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Aug 19, 2022 12:05pm

166 Views

Post# 34907562

RE:RE:RE:RE:RE:RE:RE:RE:RE:total liabilities dropped by $8M in H1

Nasdaq listing was premature as all it did was further dilute shareholders wealth and made the Boston Group hold more. Go back 2 Years and study all the PR's and you will notice they are cheating the common shareholder.

Mark my words;

There will never be a small time Canadian Company that will solve ALS or Dementia. NEVER.

There are TONS of companies DECADES ahead of PMN.

Thank GOD I sold at 11.50 CAD after the Nasdaq Listing but bought more at 7.00 CAD, mistake.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing